Treatment of idiopathic focal segmental glomerulosclerosis: Options in the event of resistance to corticosteroids and calcineurin inhibitors;Tratamiento de la glomeruloesclerosis focal y segmentaria idiopática: Opciones en caso de resistencia a corticosteroides y anticalcineurínicos

Nefrologia

Volumn 33, Issue 4, 2013, Pages 448-461

  Segarra Medrano, Alfonso ^a   Jatem Escalante, Elias ^a   Agraz Pamplona, Irene ^a   Carnicer Cáceres, Clara ^a   Ramos Terrades, Natalia ^a   Ostos Roldán, Elena ^a   Teresa Quiles Perez M ^a   Antonia Arbos Via M ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Idiopathic focal glomerulosclerosis; Resistance to calcineurin inhibitors; Steroid resistance

Indexed keywords

CALCINEURIN; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT;

DRUG ANTAGONISM; DRUG RESISTANCE; FOCAL GLOMERULOSCLEROSIS; FORECASTING; HUMAN; REVIEW;

ADRENAL CORTEX HORMONES; CALCINEURIN; DRUG RESISTANCE; FORECASTING; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 84883043154     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2013.Jan.11871     Document Type: Review

References (112)

1. D'Agati V. Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol 2003;23:117-34.
2. Korbet SM. Treatment of Primary FSGS in Adults. J Am Soc Nephrol 2012;23:1769-76.
3. Quereda C, Ballarín J. Síndrome nefrÓtico por glomerulosclerosis focal segmentaria del adulto. Nefrologia 2007;27 Suppl 2:56-69.
4. Meyrier A. Management of idiopathic nephrotic syndrome in adults: minimal change disease and focal segmental glomerulosclerosis. In: Molony DA, Craig JC (eds.). Evidence-based nephrology (4th ed.). Oxford: Wiley-Blackwell; 2009. p. 149-57.
5. Meyrier A. An update on the treatment options for focal segmental glomerulosclerosis. Expert Opin Pharmacother 2009;10:615-28.
6. KDIGO. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Idiopathic focal glomerulosclerosis in adults. Kidney Int Suppl 2012;2:181-5.
7. Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 2004;15:2169-77.
8. Stirling CM, Mathieson P, Boulton-Jones JM, Feehally J, Jayne D, Murray HM, et al. Treatment and outcome of adult patients with primary focal segmental glomerulosclerosis in five UK renal units. QJM 2005;98:443-9.
9. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry Group. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol 2005;16:1061-8.
10. Miyata J, Takebayashi S, Taguchi T, Naito S, Harada T. Evaluation and correlation of clinical and histological features of focal segmental glomerulosclerosis. Nephron 1986; 44:115-20.
11. Agarwal SK, Dash SC, Tiwari SC, Bhuyan UN. Idiopathic adult focal segmentalglomerulosclerosis: a clinicopathological study and response to steroid. Nephron 1993;63:168-71.
12. Pei Y, Cattran D, Delmore T, Katz A, Lang A, Rance P. Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis.Regional Glomerulonephritis Registry Study. Am J Med 1987;82:938-44.
13. Banfi G, Moriggi M, Sabadini E, Fellin G, D'Amico G, Ponticelli C. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol 1991;36:53-9.
14. Rydel JJ, Korbet SM, Borok RZ, Schwartz MM. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis 1995;25:534-42.
15. Ponticelli C, Villa M, Banfi G, Cesana B, Pozzi C, Pani A, et al. Can prolonged treatment improve the prognosis in adultswith focal segmental glomerulosclerosis. Am J Kidney Dis 1999;34:618-25.
16. Cattran DC, Rao P. Long-term outcome in children and adults with classic focalsegmental glomerulosclerosis. Am J Kidney Dis 1998;32:72-9.
17. Pokhariyal S, Gulati S, Prasad N, Sharma RK, Singh U, Gupta RK, et al. Duration of optimal therapy for idiopathic focal segmental glomerulosclerosis. J Nephrol 2003;16:691-6.
18. Pollak MR. Focal segmental glomerulosclerosis: recent advances. Curr Opin Nephrol Hypertens 2008;17:138-42.
19. McCarthy ET, Sharma M, Savin VJ. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2010;5:2115-21.
20. Schönenberger E, Ehrich JH, Haller H, Schiffer M. The podocyte as a direct target of immunosuppressive agents. Nephrol Dial Transplant 2011;26:18-24.
21. Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1993;43:1377-84.
22. Meyrier A, Noël LH, Auriche P, Callard P. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Société de Néphrologie. Kidney Int 1994;45:1446-56.
23. Niaudet P. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology. J Pediatr 1994;125:981-6.
24. Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol 1996;7:56-63.
25. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 1999;56:2220-6.
26. Heering P, Braun N, Müllejans R, Ivens K, Zäuner I, Fünfstück R, et al.; German Collaborative Glomerulonephritis Study Group. Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. Am J Kidney Dis 2004;43:10-8.
27. Segarra A, Vila J, Pou L, Majó J, Arbós A, Quiles T, et al. Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Nephrol Dial Transplant 2002;17:655-62.
28. Loeffler K, Gowrishankar M, Yiu V. Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. Pediatr Nephrol 2004;19:281-7.
29. Li X, Li H, Ye H, Li Q, He X, Zhang X, et al. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR. Am J Kidney Dis 2009;54:51-8.
30. Duncan N, Dhaygude A, Owen J, Cairns TD, Griffith M, McLean AG, et al. Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol Dial Transplant 2004;19:3062-7.
31. Choudhry S, Bagga A, Hari P, Sharma S, Kalaivani M, Dinda A. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. Am J Kidney Dis 2009;53:760-9.
32. Radhakrishnan J, Wang MM, Matalon A, Cattran DC, Appel GB. Mycophenolate mofetil treatment of idiopathic focal segmental glomerulosclerosis [Abstract]. J Am Soc Nephrol 1999;114A:A584.
33. Al-Lehbi AM, Al-Mutairi MA, Al-Meshari KA, Alfurayh OI. Mycophenolate mofetil in steroid resistant focal segmental glomerulosclerosis [Abstract]. J Am Soc Nephrol 1999;94A:A483.
34. Choi MJ, Eustace JA, Gimenez LF, Atta MG, Scheel PJ, Sothinathan R, et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002;61:1098-114.
35. Day CJ, Cockwell P, Lipkin GW, Savage CO, Howie AJ, Adu D. Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant 2002;17:2011-3.
36. Nikibakhsh AA, Mahmoodzadeh H, Karamyyar M, Hejazi S, Noroozi M, Macooie AA. Treatment of steroid and cyclosporine-resistant idiopathic nephrotic syndrome in children. Int J Nephrol 2011;2011:930965.
37. Sahin GM, Sahin S, Kantarci G, Ergin H. Mycophenolate mofetil treatment for therapy-resistant glomerulopathies. Nephrology (Carlton) 2007;12:285-8.
38. Cattran DC, Wang MM, Appel G, Matalon A, Briggs W. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 2004;62:405-11.
39. Segarra A, Amoedo ML, Martinez Garcia JM, Pons S, Praga M, Garcia EI, et al. Efficacy and safety of 'rescue therapy' with mycophenolate mofetil in resistant primary glomerulonephritis-a multicenter study. Nephrol Dial Transplant 2007;22:1351-60.
40. Montané B, Abitbol C, Chandar J, Strauss J, Zilleruelo G. Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade. Pediatr Nephrol 2003;18:772-7.
41. Gargah TT, Lakhoua MR. Mycophenolate mofetil in treatment of childhood steroid-resistant nephrotic syndrome. J Nephrol 2011;24:203-7.
42. Gipson DS, Trachtman H, Kaskel FJ, Greene TH, Radeva MK, Gassman JJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 2011;80:868-78.
43. Tumlin JA, Miller D, Near M, Selvaraj S, Hennigar R, Guasch A. A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2006;1:109-16.
44. Liern M, Dereyes V, Fayad A, Vallejo G. Use of sirolimus in patients with primary steroid-resistant nephrotic syndrome. Nefrologia 2012;32:321-8.
45. Cho ME, Hurley JK, Kopp JB. Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity. Am J Kidney Dis 2007;49:310-7.
46. Geary DF, Farine M, Thorner P, Baumal R. Response to cyclophosphamide in steroid-resistant focal segmental glomerulosclerosis: a reappraisal. Clin Nephrol 1984;22:109-13.
47. Cade R, Mars D, Privette M, Thompson R, Croker B, Peterson J, et al. Effect of long-term azathioprine administration in adults with minimal- change glomerulonephritis and nephrotic syndrome resistant to corticosteroids. Arch Intern Med 1986;146:737-41.
48. Ochi A, Takei T, Nakayama K, Iwasaki C, Kamei D, Tsuruta Y, et al. Rituximab treatment for adult patients with focal segmental glomerulosclerosis. Intern Med 2012;51:759-62.
49. Zachwieja J, Silska M, Ostalska-Nowicka D, Soltysiak J, Lipkowska K, Blumczynski A, et al. Efficacy and safety of rituximab treatment in children with primary glomerulonephritis. J Nephrol 2012;25(6):1060-6.
50. Kari JA, El-Morshedy SM, El-Desoky S, Alshaya HO, Rahim KA, Edrees BM. Rituximab for refractory cases of childhood nephrotic syndrome. Pediatr Nephrol 2011;26:733-7.
51. Fernandez-Fresnedo G, Segarra A, González E, Alexandru S, Delgado R, Ramos N, et al; Trabajo de Enfermedades Glomerulares de la Sociedad Española deNefrología (GLOSEN). Rituximab treatment of adult patients with steroid-resistantfocal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2009;4:1317-23.
52. Hirano D, Fujinaga S, Nishizaki N. The uncertainty of rituximab and steroid dosing in refractory steroid-resistant nephrotic syndrome. Clin Nephrol 2012;77:510-2.
53. Hristea D, Hadaya K, Marangon N, Buhler L, Villard J, Morel P, et al. Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl Int 2007;20:102-5.
54. Meyer TN, Thaiss F, Stahl RA. Immunoadsorbtion and rituximab therapy in a second living-related kidney transplant patient with recurrent focal segmental glomerulosclerosis. Transpl Int 2007;20:1066-71.
55. El-Firjani A, Hoar S, Karpinski J, Bell R, Deschenes MJ, Knoll GA. Posttransplant focal segmental glomerulosclerosis refractory to plasmapheresis and rituximab therapy. Nephrol Dial Transplant 2008;23:425.
56. Bayrakci US, Baskin E, Sakalli H, Karakayali H, Haberal M. Rituximab for post-transplant recurrences of FSGS. Pediatr Transplant 2009;13:240-3.
57. Hickson LJ, Gera M, Amer H, Iqbal CW, Moore TB, Milliner DS, et al. Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation 2009;87:1232-9.
58. Damodar A, Mustafa R, Bhatnagar J, Panesar M, Gundroo A, Zachariah M, et al. Use of anti-CD20 antibody in the treatment of post-transplant glomerulonephritis. Clin Transplant 2011;25:375-9.
59. Vinai M, Waber P, Seikaly MG. Recurrence of focal segmental glomerulosclerosisin renal allograft: an in-depth review. Pediatr Transplant 2010;14:314-25.
60. Sakai K, Takasu J, Nihei H, Yonekura T, Aoki Y, Kawamura T, et al. Protocol biopsies for focal segmental glomerulosclerosis treated with plasma exchange and rituximab in a renal transplant patient. Clin Transplant 2010;24 Suppl 22:60-5.
61. Tsagalis G, Psimenou E, Nakopoulou L, Laggouranis A. Combination treatment with plasmapheresis and rituximab for recurrent focal segment glomerulosclerosis after renal transplantation. Artif Organs 2011;35:420-5.
62. Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 2011;3:85ra46.
63. Kemper MJ, Wolf G, Müller-Wiefel DE. Transmission of glomerular permeability factor from a mother to her child. N Engl J Med 2001;344:386-7.
64. Ginsburg DS, Dau P. Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis. Clin Nephrol 1997;48:282-7.
65. Mitwalli AH. Adding plasmapheresis to corticosteroids and alkylating agents: does it benefit patients with focal segmental glomerulosclerosis. Nephrol Dial Transplant 1998;13:1524-28.
66. Feld SM, Figueroa P, Savin V, Nast CC, Sharma R, Sharma M, et al. Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys. Am J Kidney Dis 1998;32: 230-7.
67. Godfrin Y, Dantal J, Bouhours JF, Heslan JM, Soulillou JP. A new method of measuring albumin permeability in isolated glomeruli. Kidney Int 1996;50:1352-7.
68. Haas M, Godfrin Y, Oberbauer R, Yilmaz N, Borchhardt K, Regele H, et al. Plasma immunadsorption treatment in patients with primary focal and segmental glomerulosclerosis. Nephrol Dial Transplant 1998;13:2013-6.
69. Cattran D, Neogi T, Sharma R, McCarthy ET, Savin VJ. Serial estimates of serum permeability activity and clinical correlates in patients with native kidney focal segmental glomerulosclerosis. J Am Soc Nephrol 2003;14:448-53.
70. Moriconi L, Lenti C, Puccini R, Pasquariello A, Rindi P, Batini V, et al. Proteinuria in focal segmental glomerulosclerosis: role of circulating factors and therapeutic approach. Ren Fail 2001;23:533-41.
71. Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011;17:952-60.
72. Stenvinkel P, Alvestrand A, Angelin B, Eriksson M. LDL-apheresis in patients with nephrotic syndrome: effects on serum albumin and urinary albumin excretion. Eur J Clin Invest 2000;30:866-70.
73. Hattori M, Chikamoto H, Akioka Y, Nakakura H, Ogino D, Matsunaga A, et al. A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis 2003;42:1121-30.
74. Muso E, Mune M, Yorioka N, Nishizawa Y, Hirano T, Hattori M, et al. Beneficial effect of low-density lipoprotein apheresis (LDL-A) on refractory nephrotic syndrome (NS) due to focal glomerulosclerosis (FGS). Clin Nephrol 2007;67:341-4.
75. Segarra Medrano A, Vila Presas J, Pou Clavé L, Majó Masferrer J, Camps Doménech J. Efficacy and safety of combined cyclosporin A and mycophenolate mofetil therapy in patients with cyclosporin-resistant focal segmental glomerulosclerosis. Nefrologia 2011;31:286- 91.
76. Youssef DM, Elbehidy RM, Abdelhalim HS, Amr GE. Soluble interleukine- 2 receptor and MDR1 gene expression levels as inflammatory biomarkers for prediction of steroid response in children with nephrotic syndrome. Iran J Kidney Dis 2011;5:154-61.
77. Bradley G, Juranka PF, Ling V. Mechanism of multidrug resistance. Biochim Biophys Acta 1988;948:87-128.
78. Meijer OC, de Lange EC, Breimer DD, de Boer AG, Workel JO, de Kloet ER. Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. Endocrinology 1998;139:1789-93.
79. Masters JR. Biochemical basis of resistance to chemotherapy. Radiother Oncol 1990;19:297-305.
80. Webster JI, Carlstedt-Duke J. Involvement of multidrug resistance proteins (MDR) in the modulation of glucocorticoid response. J Steroid Biochem Mol Biol 2002;82:277-88.
81. Tsujimura S, Saito K, Nakayamada S, Nakano K, Tanaka Y. Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus. Arthritis Rheum 2005;52:1676-83.
82. Maillefert JF, Maynadie M, Tebib JG, Aho S, Walker P, Chatard C, et al. Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone. Br J Rheumatol 1996;35: 430-5.
83. Wasilewska AM, Zoch-Zwierz WM, Pietruczuk M. Expression of Pglycoprotein in lymphocytes of children with nephrotic syndrome treated with glucocorticoids. Eur J Pediatr 2006;165:839-44.
84. Wasilewska A, Zoch-Zwierz W, Pietruczuk M. Expression of multidrug resistance P-glycoprotein on lymphocytes from nephrotic children treated with cyclosporine A and ACE-inhibitor. Eur J Pediatr 2007;166:447-52.
85. Funaki S, Takahashi S, Wada N, Murakami H, Harada K. Multiple drug-resistant gene 1 in children with steroid-sensitive nephrotic syndrome. Pediatr Int 2008;50:159-61.
86. Praga M. Tratamiento de la glomeruloesclerosis segmentaria y focal. Nefrologia 2005;25:612-21.
87. Machuca E, Hummel A, Nevo F, Dantal J, Martinez F, Al-Sabban E, et al. Clinical and epidemiological assessment of steroid-resistant nephrotic syndrome associated with the NPHS2 R229Q variant. Kidney Int 2009;75:727-35.
88. McKenzie LM, Hendrickson SL, Briggs WA, Dart RA, Korbet SM, Mokrzycki MH, et al. NPHS2 variation in sporadic focal segmental glomerulosclerosis. J Am Soc Nephrol 2007;18:2987-95.
89. He N, Zahirieh A, Mei Y, Lee B, Senthilnathan S, Wong B, et al. Recessive NPHS2 (Podocin) mutations are rare in adult-onset idiopathic focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007;2:31-7.
90. Tonna SJ, Needham A, Polu K, Uscinski A, Appel GB, Falk RJ, et al. NPHS2 variation in focal and segmental glomerulosclerosis. BMC Nephrol 2008;9:13.
91. Santín S, Bullich G, Tazón-Vega B, García-Maset R, Giménez I, Silva I et al. Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2011;6:1139-48.
92. Rood IM, Deegens JK, Wetzels JF. Genetic causes of focal segmental glomerulosclerosis: implications for clinical practice. Nephrol Dial Transplant 2012;27:882-90.
93. Ruf RG, Lichtenberger A, Karle SM, Haas JP, Anacleto FE, Schultheiss M, et al.; Arbeitsgemeinschaft Für Pädiatrische Nephrologie Study Group. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 2004;15:722-32.
94. Peyser A, Machardy N, Tarapore F, Machardy J, Powell L, Gipson DS, et al. Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group. BMC Nephrol 2010;29:2.
95. Joy MS, Gipson DS, Powell L, MacHardy J, Jennette JC, Vento S, et al. Phase 1 trial of adalimumab inFocal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am J Kidney Dis 2010;55:50-60.
96. Trachtman H, Vento S, Gipson D, Wickman L, Gassman J, Joy M, et al. Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design. BMC Nephrol 2011;12:8.
97. Trachtman H, Fervenza FC, Gipson DS, Heering P, Jayne DR, Peters H. A phase 1, single-dose study of fresolimumab, an anti-TGF- β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 2011;79:1236-43.
98. Bomback AS, Tumlin JA, Baranski J, Bourdeau JE, Besarab A, Appel AS, et al. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel. Drug Des Devel Ther 2011;5:147- 53.
99. Savin VJ, McCarthy ET, Sharma R, Charba D, Sharma M. Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. Transl Res 2008;151:288-92.
100. De Smet E, Rioux JP, Ammann H, Déziel C, Quérin S. FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy. Nephrol Dial Transplant 2009;24:2938-40.
101. Jhaveri KD, Naber TH, Wang X, Molmenti E, Bhaskaran M, Boctor FN, et al. Treatment of recurrent focal segmental glomerular sclerosis posttransplant with a multimodal approach including highgalactose diet and oral galactose supplementation. Transplantation 2011;91:e35-6.
102. Kopac M, Meglic A, Rus RR. Partial remission of resistant nephrotic syndrome after oral galactose therapy. Ther Apher Dial 2011;15:269-72.
103. Garin EH, Diaz LN, Mu W, Wasserfall C, Araya C, Segal M, et al. Urinary CD80 excretion increases in idiopathic minimal-change disease. J Am Soc Nephrol 2009;20:260-6.
104. Garin EH, Mu W, Arthur JM, Rivard CJ, Araya CE, Shimada M, et al. Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis. Kidney Int 2010;78:296-302.
105. Regele HM, Fillipovic E, Langer B, Poczewki H, Kraxberger I, Bittner RE, et al. Glomerular expression of dystroglycans is reduced in minimal change nephrosis but not in focal segmental glomerulosclerosis. J Am Soc Nephrol 2000;11:403-12.
106. Giannico G, Yang H, Neilson EG, Fogo AB. Dystroglycan in the diagnosis of FSGS. Clin J Am Soc Nephrol 2009;4:1747-53.
107. Woroniecki RP, Shatat IF, Supe K, Du Z, Kaskel FJ. Urinary cytokines and steroid responsiveness in idiopathic nephrotic syndrome of childhood. Am J Nephrol 2008;28:83-90.
108. Tripathi G, Jafar T, Mandal K, Mahdi AA, Awasthi S, Sharma RK, et al. Does cytokine gene polymorphism affect steroid responses in idiopathic nephrotic syndrome. Indian J Med Sci 2008;62:383- 91.
109. Woroniecki RP, Orlova TN, Mendelev N, Shatat IF, Hailpern SM, Kaskel FJ, et al. Urinary proteome of steroid-sensitive and steroidresistant idiopathic nephrotic syndrome of childhood. Am J Nephrol 2006;26:258-67.
110. Traum AZ. Urine proteomic profiling to identify biomarkers of steroid resistance in pediatric nephrotic syndrome. Expert Rev Proteomics 2008;5:715-19.
111. Piyaphanee N, Ma Q, Kremen O, Czech K, Greis K, Mitsnefes M, et al. Discovery and initial validation of a 1-B glycoprotein fragmentation as a differential urinary biomarker in pediatric steroid-resistant nephrotic syndrome. Proteomics Clin Appl 2011;5:334-42.
112. Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, et al., for the PodoNet and FSGS CT Study Consortia. Circulating suPAR in Two Cohorts of Primary FSGS. J Am Soc Nephrol 2012;23:2051-9.